top of page


Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
09/09/2026 UCB received US FDA BTD for CIMZIA in pregnant women with antiphospholipid syndrome. Beeline Medicines announced topline results from the Phase 2 study of afimetoran in SLE. UCB received US FDA BTD for CIMZIA in pregnant women with antiphospholipid syndrome. (Ref) UCB announced that the US FDA had granted Breakthrough Therapy Designation (BTD) to CIMZIA® (certolizumab pegol) for the prevention of placenta-mediated adverse pregnancy outcomes in addition to standard
decodeMR Team
Sep 101 min read
bottom of page